Zobrazeno 1 - 10
of 38
pro vyhledávání: '"Patricia A. Seymour"'
Autor:
Mihály Hajós, William E. Hoffman, John F. Harms, Mary Piotrowski, Christopher J. Schmidt, Eric P. Arnold, Robin J. Kleiman, Edward X. Yang, Adam Ogden, Patricia A. Seymour, Jiemin Lu, Ethan Lawrence Fisher, Nichole Vansell, Patrick Robert Verhoest, Jayvardhan Pandit, Zhijun Kang, Hirokazu Ueno, John M. Humphrey, Bethany L. Kormos, Dina McGinnis, Thomas Allen Chappie, Noha Maklad, Laura McDowell, Cheng Chang, Rebecca E. O’Connor, Chewah Lee, Tracey Boyden, Christopher J. O’Donnell, Christopher John Helal
Publikováno v:
Journal of medicinal chemistry. 61(3)
Computational modeling was used to direct the synthesis of analogs of previously reported phosphodiesterase 2A (PDE2A) inhibitor 1 with an imidazotriazine core to yield compounds of significantly enhanced potency. The analog PF-05180999 (30) was subs
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::408cc7b21c310fe120ce681146fe8fb5
https://pubmed.ncbi.nlm.nih.gov/29293004
https://pubmed.ncbi.nlm.nih.gov/29293004
Autor:
Amy B. Dounay, Kari R. Fonseca, Graham V. Williams, Christine A. Strick, Douglas S. Chapin, Mihály Hajós, Amanda L. Abbott, Damon Young, William E. Hoffmann, Dina McGinnis, Weldon Horner, Tamás Kiss, Brooke M. Roberts, Rouba Kozak, Victor Guanowsky, Patricia A. Seymour, Brian M. Campbell, Stacy A. Castner
Publikováno v:
Journal of Neuroscience. 34:10592-10602
The elevation of kynurenic acid (KYNA) observed in schizophrenic patients may contribute to core symptoms arising from glutamate hypofunction, including cognitive impairments. Although increased KYNA levels reduce excitatory neurotransmission, KYNA h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::44a6047a2dd863fcfb3f794b280e2b69
https://doi.org/10.1523/jneurosci.1107-14.2014
https://doi.org/10.1523/jneurosci.1107-14.2014
Publikováno v:
Psychopharmacology. 231:2189-2197
Inhibitors of phosphodiesterase 10A (PDE10A), an enzyme highly expressed in medium spiny neurons of the mammalian striatum, enhance activity in direct (dopamine D1 receptor-expressing) and indirect (D2 receptor-expressing striatal output) pathways. T
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::edb7e10c000e41afb52ab01fd1d67172
https://doi.org/10.1007/s00213-013-3371-7
https://doi.org/10.1007/s00213-013-3371-7
Publikováno v:
Behavioural Brain Research. 252:405-414
Social withdrawal is one of several negative symptoms of schizophrenia, all of which are poorly treated by current therapies. One challenge in developing agents with efficacy against negative symptoms is the lack of suitable preclinical models. The s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d09843213711d11204ebf1b4d64a18aa
https://doi.org/10.1016/j.bbr.2013.06.017
https://doi.org/10.1016/j.bbr.2013.06.017
Autor:
Michelle Vanase-Frawley, Diane Stephenson, Patrick Robert Verhoest, Mihály Hajós, Geralyn P. Kocan, William E. Hoffmann, Kari R. Fonseca, Douglas S. Chapin, Christopher J. Schmidt, Fredrick R. Nelson, Curt Christoffersen, Frank S. Menniti, Jody Freeman, Stafford McLean, Victor Guanowsky, Kieran F. Geoghegan, Mark J. Majchrzak, Christopher John Helal, Patricia A. Seymour, John F. Harms, Sarah Grimwood, Francis David Tingley, Robin J. Kleiman, Robin Roof, Anne W. Schmidt, Dina McGinnis
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 341:396-409
Cyclic nucleotides are critical regulators of synaptic plasticity and participate in requisite signaling cascades implicated across multiple neurotransmitter systems. Phosphodiesterase 9A (PDE9A) is a high-affinity, cGMP-specific enzyme widely expres
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e434253f25e37a0d7e9a05a69e8cdd81
https://doi.org/10.1124/jpet.111.191353
https://doi.org/10.1124/jpet.111.191353
Autor:
Mary Piotrowski, Allen J. Duplantier, Christine A. Strick, Brian D. Harvey, Mark J. Majchrzak, Cheryl Li, Patricia A. Seymour, Christopher J. Schmidt, Carol B. Fox, Alan H. Ganong, Larry C. James, F. David Tingley, Andres D. Ramirez, James T. Downs, Mihály Hajós, Victor Guanowsky, Liam Scott, Stacey L. Becker, Youfen Xu, Stefanus J. Steyn, Ayman El-Kattan, Brian Rago
Publikováno v:
Neuropharmacology. 61:1001-1015
Observations that N-Methyl-D-Aspartate (NMDA) antagonists produce symptoms in humans that are similar to those seen in schizophrenia have led to the current hypothesis that schizophrenia might result from NMDA receptor hypofunction. Inhibition of D-a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::29d50eb849564a55d05e9986564219f8
https://doi.org/10.1016/j.neuropharm.2011.06.029
https://doi.org/10.1016/j.neuropharm.2011.06.029
Autor:
Brian T. O’Neill, Emily B. Einstein, Patricia A. Seymour, Marina R. Picciotto, Yann S. Mineur, Hans Rollema, Jotham Wadsworth Coe
Publikováno v:
Behavioural Pharmacology. 22:291-299
Previous studies have suggested that treatment with antagonists or partial agonists of nicotinic acetylcholine receptors containing the β2 subunit (β2* nAChRs) results in antidepressant-like effects. In the current study we tested 3 novel compounds
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::54139f065b1eb391fee7a8f2eec38411
https://doi.org/10.1097/fbp.0b013e328347546d
https://doi.org/10.1097/fbp.0b013e328347546d
Autor:
Patricia A. Seymour, Christopher L. Shaffer, Brooke M. Roberts, Graham V. Williams, Christopher J. Schmidt, Stacy A. Castner
Publikováno v:
NeuroReport. 21:390-394
Glycine transporter inhibitors have recently been reported to improve symptoms in patients with schizophrenia. Here we used acute ketamine in the nonhuman primate to test the effectiveness of the novel glycine transporter inhibitor, PF-3463275, in a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1f2f80c1e37e103c0e10e9fba73c281f
https://doi.org/10.1097/wnr.0b013e3283381a4e
https://doi.org/10.1097/wnr.0b013e3283381a4e
Autor:
David E. Johnson, Rouba Kozak, Mark J. Majchrzak, Mihály Hajós, Kathryn E. Williams, William E. Hoffmann, Hans Rollema, Patricia A. Seymour, Doug S. Chapin, Stafford McLean, Victor Guanowsky, Weldon Horner, Jody Freeman
Publikováno v:
Biochemical Pharmacology. 78:813-824
The pharmacological properties and pharmacokinetic profile of the alpha4beta2 nicotinic acetylcholine receptor (nAChR) partial agonist varenicline provide an advantageous combination of free brain levels and functional potencies at the target recepto
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bc35e34c456e3d48f7c746cdd4c74149
https://doi.org/10.1016/j.bcp.2009.05.033
https://doi.org/10.1016/j.bcp.2009.05.033